#FDA #uniQure #AMT-130

Allegations against uniQure: A Closer Look

In a shocking turn of events, uniQure N.V. (NASDAQ: QURE) has found itself embroiled in controversy following accusations from federal health officials regarding its clinical data related to the gene therapy drug AMT-130, aimed at combating Huntington's disease. This revelation comes on the heels of a pending securities class action lawsuit that could have dire consequences for the company and its investors.

Background of the Controversy

The national law firm Hagens Berman recently announced an update to its investigation into uniQure, prompted by a report in The Wall Street Journal that outlined unprecedented criticism from the Food and Drug Administration (FDA). The agency's officials reportedly described the data from uniQure's trials as flawed, suggesting that AMT-130 does not meet the necessary standards for approval. This public rebuke has sent shockwaves through the biotech community, given that the drug represents a crucial advancement in gene therapy.

Details of the Claims

According to the report dated March 5, 2026, a senior FDA official accused uniQure of misrepresenting the agency's requests concerning the clinical trial designs. In a heated discussion with journalists, it was alleged that executive mischaracterizations had led to a significant mishandling of clinical data, which officials termed as